14
May

08:00 AM ET

Drug Discovery Biology

Name: Drug Discovery Biology & Bioinformatics Strategy Meeting East Coast 2024
Start: 2024-05-14T08:00
End: 2024-05-14T18:00
Location: Hyatt Regency Princeton

&

Bioinformatics

Strategy Meeting East Coast USA 2024

Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space

Hyatt Regency Princeton

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh R&D Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology and Bioinformatics professionals from across the East Coast, in Princeton, New Jersey, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.

Aaron Mackey

Former SVP, AI & Data Science Sonata Therapeutics

Abhijat Vatsyayan

Head of Artificial Intelligence Taiho Oncology

Andrew Zhang

Director, Head of Chemical Biology AstraZeneca

Angela Huang

Founder and President Tempo Bioscience

Christopher Conway

President, Research and Development Curia

Chris is a seasoned business executive with a 25 year strong track record across a variety of industry verticals including aerospace, pharmaceutical/biotech and contract research, development, and manufacturing. Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Currently, Chris serves as President and R&D Business Unit Head at Curia, a global top ten organization in contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris also currently serves as a Director on the board of two Life Sciences organizations including Viyash Life Sciences Private Limited, a Carlyle owned company, as well as the Drug, Chemical & Associated Technologies Association, Inc. (DCAT). Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences

Claudette Fuller

Vice President, Head of Non-Clinical Safety & Toxicology Genmab

Douglas Kitchen

Research Fellow, Medicinal Chemistry Curia

Ernane Souza, PhD, RPh

Assistant Director, Translational PKPD and DMPK Supernus Pharmaceuticals Inc

Frank Leu

Founder & Managing Member/ Managing Member BioPharMatrix LLC/ Novapeutics LLC

Greg Williams

Senior Research Scientist II, Cellular Assay Technologies Curia

Dr. Gregory Williams, Senior Research Scientist II, joined Curia in 2020. He serves as the Cell- Based Assay Technologies (CBAT) team leader at Curia’s Integrated Drug Discovery facility in Buffalo, NY. Dr. Williams and his team work to develop cell-based models of human disease using a combination of approaches to support both large-molecule and small-molecule discovery. He has over 10 years’ experience in cell-based assay development and screening of small molecules and has managed more than 150 client based projects in the fields of immunology, oncology, and neurobiology. Leveraging state-of-the-art high content screening tools, automation, and multiplex analysis approaches, Dr. Williams and his team work towards delivering innovative, predictive, and cost-effective assays that drive pre-clinical drug discovery programs. Dr. Williams received his PhD in Biochemistry at the University at Buffalo, where he published work in journals such as Cell and Nature. As a Government of Ireland Postdoctoral Fellow, he investigated the role of small-molecule histone deacetylase inhibitors in the progression of Huntington’s disease at the National University of Ireland in Galway.

Dr. Grant Carr

Vice President, Head of Global R&D Drug Discovery Curia

Gunaretnam Rajagopal

Venture Partner Samsara Biocapital

Guna’s expertise encompasses the fields of Data Sciences, AI/Machine Learning, Bioinformatics, Computational, Systems Biology & Pharmacology, Genetics & Genomics, High Performance Computing and Theoretical & Computational Physics. He has led global initiatives focused on advancing cross-disciplinary basic research, translational & clinical programs in collaboration with academia and national/international pre-competitive consortiums. Guna’s academic career spans undergraduate degree from the University of Malaya (1986), PhD in Computational & Theoretical Physics from Georgia Tech (1987-1991), post-doctoral training at the Cavendish Laboratory, University of Cambridge, rising to Assistant Director of Research and elected a Fellow of Jesus College Cambridge (1991-2000). He was the founding Executive Director of the Bioinformatics Institute at the BIOPOLIS, Singapore (2000-2007), led the Bioinformatics & Systems Biology program at the Rutgers Cancer Institute of New Jersey with a joint appointment as Adjunct Professor at the Robert Wood Johnson Medical School and as a Member of Advanced Studies in Princeton (2007-2012). He joined Janssen R&D to lead efforts to develop and deploy Computational Analytics, Informatics and Data Science capabilities to support global discovery, translational, development and clinical programs (2012-2022). He retired as Scientific Fellow and Global Head of Computational Sciences and joined Samsara Biocapital as a Venture Partner.)

Marcie Glicksman

Vice President, Biology Enclear Therapies

Mark Tornetta

VP of Biologics Discovery Tavotek Biotherapeutics

ML Ujwal

Associate Director, Data Science Johnson & Johnson

Nikolaos Tezapsidis

President & CEO Neurotez Inc.

Paul Kayne

Vice President, Biological Sciences Palatin Technologies

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

08:00 – 08:30

Mechanistic understanding of E3 ligase engagement: Yesterday’s news or hidden secrets?

PRESENTER: Andrew Zhang, Director, Head of Chemical Biology, AstraZeneca

09:00 – 10:00

Roundtable Tracks

Target Identification & Hit Validation
Maximizing The Potentials Of Multiomics In Target Identification And Safety Profiling

-Paul Kayne
Vice President, Biological Sciences
Palatin Technologies

DMPK / ADME & Toxicology
Advancing Drug Discovery and Safety Assessment with AI/ML: Where We Are And Where We Re Going

-Claudette Fuller
Vice President, Head of Non-Clinical Safety & Toxicology
Genmab

In Vivo and In Vitro Pharmacology
Latest Approaches And Trends For Improving Nonclinical Studies

-Angela Huang
Founder and President
Tempo Bioscience

In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Harnessing The Promise Of Generative AI To Transform Drug Discovery Hence Forward

-Aaron Mackey
Former SVP, AI & Data Science
Sonata Therapeutics

Strategic Partnerships, Investment & Collaborations
Forming Strategic Partnerships:
Collaboration or M&A?

-Nikolaos Tezapsidis
President & CEO
Neurotez Inc.

11:10 – 12:10

Roundtable Tracks

Target Identification & Hit Validation
Probing ways to access greater target space and expand the druggable genome to a larger therapeutic area to discover new drugs

-Greg Williams
Senior Research Scientist II, Cellular Assay Technologies
Curia

Curia

DMPK / ADME & Toxicology
Integrating Breakthroughs In In Silico In Vivo And In Vitro Pharmacology To Enhance ADMET Modeling

-Dr. Grant Carr
Vice President, Head of Global R&D Drug Discovery
Curia

Curia

In Vivo and In Vitro Pharmacology

In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Leveraging AI Target Selection Technologies Strategies And Infrastructure Tools To Support Computational Biology

-Douglas Kitchen
Research Fellow, Medicinal Chemistry
Curia

Curia

Strategic Partnerships, Investment & Collaborations
Strategic Partnerships, Investment & Collaborations in drug development

-Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

12:15 – 13:15

Roundtable Tracks

Target Identification & Hit Validation
Reducing Attrition Rate By Employing Groundbreaking Technologies At Discovery Stage And Accelerate The Process

-Mark Tornetta
VP of Biologics Discovery
Tavotek Biotherapeutics

DMPK / ADME & Toxicology

In Vivo and In Vitro Pharmacology
Tackling In Vivo Complexity: Strategies for Overcoming Assay Challenges

-Marcie Glicksman
Vice President, Biology
Enclear Therapies

In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Current Adoption And Best Use Of Disruptive Techs (Blockchain, AI And ML) In Drug Discovery And Development

-Frank Leu
Founder & Managing Member/ Managing Member
BioPharMatrix LLC/ Novapeutics LLC

Strategic Partnerships, Investment & Collaborations
Strategic Partnerships in Drug Discovery: Navigating Pharma-Biotech Ecosystems and Industry-Academia Alliances

-ML Ujwal
Associate Director, Data Science
Johnson & Johnson

14:40 – 15:10

Intellectual property development in an artificially intelligent world

PRESENTER: Grant Carr, Vice President, Head of Global R&D Drug Discovery, Curia

15:10 – 16:10

Roundtable Tracks

Target Identification & Hit Validation
Navigating Target Selection and Validation in Drug Discovery: Criteria, Strategies and Models

-Marcie Glicksman
Vice President, Biology
Enclear Therapies

DMPK / ADME & Toxicology
Artificial Intelligence, ADME/Tox prediction,PBPK modeling, and Data ManagementStrategies for early drug development.

-Ernane Souza, PhD, RPh
Assistant Director, Translational PKPD and DMPK
Supernus Pharmaceuticals Inc

In Vivo and In Vitro Pharmacology

In Silico Biology / AI & ML / Blockchain and Bioinformatics Data Integration / Data Mining
Leveraging AI to Accelerate Drug Discovery and Development

-Abhijat Vatsyayan
Head of Artificial Intelligence
Taiho Oncology

Strategic Partnerships, Investment & Collaborations
Fundraising and Partnership Opportunitiesin the current BioPharma Industry

-Angela Huang
Founder and President
Tempo Bioscience

16:30 – 17:00

Tackling the pros and cons of different financing blueprint: go-to-clinic vs go-to-market vs go-to-fundraising strategies and the criteria to determine which program an organization can adapt

CHAIRPERSON: Gunaretnam Rajagopal, Venture Partner, Samsara Biocapital PANELIST: Nikolaos Tezapsidis, President & CEO, Neurotez Inc. PANELIST: Christopher Conway, President, Research and Development, Curia PANELIST: Marcie Glicksman, VP Biology,EnClear Therapies

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead our interactive Roundtable Discussions let you debate the topics that really matter

Senior Decision Makers

All our Strategy Meetings are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you

Private and Intimate Networking

Small group discussions, private meetings, networking drinks – however you choose to make those important connections our Strategy Meetings have the solution